Prometheus Research appoints vp of sales

Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.

Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.

Harker takes responsibility for developing and managing sales for the company's Research Informatics biomedical software services and new HTSQL database software for industry.

Prior to joining Prometheus, Harker held a variety of sales roles, most recently as managing director for BondDesk, a provider of software and services for fixed income trading.






You may also like

Digital

Why CGT manufacturers should automate the production process

Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Manufacturing

TrakCel to support cell and gene therapy orchestration with OCELLOS IT solution

The IT system allows cell and gene therapy (CGT) manufacturers to track the progress of personalised CGTs in real-time, while also managing their supply chain
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Manufacturing

Asymchem fully automates its therapeutic peptide manufacturing processes

The company has facilitated the scale-up of its peptide manufacturing capabilities, with its production capacity now standing at 10,000 L
Subscribe now